Novo Nordisk announced today that a Phase III trial evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease had failed to meet its primary objective.

Indeed, after an interim analysis, an independent monitoring committee concluded that the trial did not meet pre-established futility criteria, leading Novo Nordisk to discontinue the trial.

As a result, Novo Nordisk will record an impairment loss of around DKK 5.7 billion in the second quarter of 2024.

This is expected to have a negative impact on operating profit growth in 2024. The company will publish its financial results for the first six months of 2024 and outlook for the full year on August 7, 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.